FDA Announces Guidance on Enforcement of Safety Reporting Requirements for INDs and BA/BE Studies

Summary

The FDA is providing a guidance document to inform industry and investigators about the agency's plan to exercise enforcement discretion regarding safety reporting requirements for Investigational New Drug Applications and Bioavailability/Bioequivalence Studies, with the goal of giving sponsors and investigators more time to comply with the regulations.